Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16019344 | 0.83 | PSIP1 (0.43) | PSIP1HSD11B1ALDH1A1TDP1LMNA | |
| SCHEMBL10181749 | 0.83 | PSIP1 (0.43) | PSIP1HSD11B1ALDH1A1LMNATP53 | |
| SCHEMBL10292998 | 0.83 | KMT2A (0.53) | PSIP1HSD11B1ALDH1A1RAB9AMEN1 | |
| SCHEMBL28680071 | 0.81 | PSIP1 (0.59) | PSIP1HSD11B1ALDH1A1TSHRLMNA | |
| SCHEMBL10179991 | 0.80 | HSD11B1 (0.45) | HSD11B1ALDH1A1TSHRTDP1RBP4 | |
| SCHEMBL10180589 | 0.80 | TSHR (0.54) | ALDH1A1TSHRRBP4SMN1; SMN2CA2 | |
| SCHEMBL26424592 | 0.80 | CA2 (0.42) | PSIP1HSD11B1ALDH1A1TSHRTDP1 | |
| SCHEMBL9360088 | 0.79 | HSD11B1 (0.54) | HSD11B1ALDH1A1TSHRTDP1RBP4 | |
| SCHEMBL10180137 | 0.79 | ALDH1A1 (0.46) | PSIP1HSD11B1ALDH1A1TSHRTDP1 | |
| SCHEMBL7809492 | 0.77 | HSD11B1 (0.45) | HSD11B1ALDH1A1TSHRTDP1RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9765068-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20160368907-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150191432-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8940726-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140221345-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130244122-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | ONUKI MASAMICHI (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20120219866-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2475041-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME | Mitsubishi Chemical Corporation (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | USP1, UPP1, USP2 | PSIP1 731/4885HSD11B1 3270/4885ALDH1A1 598/4885 |
| US-20150191432-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PSIP1 1679/4885HSD11B1 2304/4885ALDH1A1 2460/4885 |
| US-20140221345-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PSIP1 1679/4885HSD11B1 2304/4885ALDH1A1 2460/4885 |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | PSIP1 1524/4885HSD11B1 2213/4885ALDH1A1 2705/4885 |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, UPP1, USP2 | PSIP1 731/4885HSD11B1 3270/4885ALDH1A1 598/4885 |
| US-20160368907-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PSIP1 1679/4885HSD11B1 2304/4885ALDH1A1 2460/4885 |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PSIP1 1790/4885HSD11B1 2375/4885ALDH1A1 2426/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | PSIP1 1171/4885HSD11B1 1609/4885ALDH1A1 1890/4885 |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PSIP1 1112/4885HSD11B1 2750/4885ALDH1A1 3825/4885 |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | PSIP1 1524/4885HSD11B1 2213/4885ALDH1A1 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.